Home Press Release Page 175

Press Release

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
Press Release

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

Team Business Headline -
0
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
Press Release

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Team Business Headline -
0
Enerflex Ltd. Announces Normal Course Issuer Bid
Press Release

Enerflex Ltd. Announces Normal Course Issuer Bid

Team Business Headline -
0
Enerflex Ltd. Announces Leadership Transition
Press Release

Enerflex Ltd. Announces Leadership Transition

Team Business Headline -
0
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Press Release

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Team Business Headline -
0
Pieridae Releases Q4 and Full Year 2024 Financial & Operating Results and 2024 Reserves
Press Release

Pieridae Releases Q4 and Full Year 2024 Financial & Operating Results and 2024 Reserves

Team Business Headline -
0
Bitget Wallet Partners with Cryptorefills to Enable Crypto Travel Payments in 180 Countries
Press Release

Bitget Wallet Partners with Cryptorefills to Enable Crypto Travel Payments in 180 Countries

Team Business Headline -
0
Rubicon Organics to Report Q4 2024 Results
Press Release

Rubicon Organics to Report Q4 2024 Results

Team Business Headline -
0
Integer Holdings Corporation Enhances Capitalization Structure with the Closing of $1.0 Billion Convertible Senior Notes Offering
Press Release

Integer Holdings Corporation Enhances Capitalization Structure with the Closing of $1.0 Billion Convertible Senior Notes Offering

Team Business Headline -
0
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
Press Release

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Team Business Headline -
0
1...174175176...209Page 175 of 209
error: